• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alvotech - Ordinary Shares (NQ: ALVO )

    13.84 -0.21 (-1.49%)
    Streaming Delayed Price Updated: 2:47 PM EDT, Jun 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Alvotech - Ordinary Shares

    < Previous 1 2 3 4 Next >
    Alvotech Completes $137 Million Private Share Placement
    From Alvotech
    Via GlobeNewswire
    Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
    From Alvotech
    Via GlobeNewswire
    Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
    From Alvotech
    Via GlobeNewswire
    Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
    From Alvotech
    Via GlobeNewswire
    Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
    From Alvotech
    Via GlobeNewswire
    Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
    From Alvotech
    Via GlobeNewswire
    Alvotech Completes $59.7 Million Private Placement
    From Alvotech
    Via GlobeNewswire
    Alvotech Shares Start Trading on Nasdaq Iceland Main Market
    From Alvotech
    Via GlobeNewswire
    Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
    From Alvotech
    Via GlobeNewswire
    Alvotech Announces Changes to its Leadership Team
    From Alvotech
    Via GlobeNewswire
    Alvotech Secures Financing Facilities of Approximately $136 Million
    From Alvotech
    Via GlobeNewswire
    Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
    From Alvotech
    Via GlobeNewswire
    Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
    From Alvotech
    Via GlobeNewswire
    Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
    From Alvotech
    Via GlobeNewswire
    Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
    From Alvotech
    Via GlobeNewswire
    Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
    From Alvotech
    Via GlobeNewswire
    Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
    From Alvotech
    Via GlobeNewswire
    Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
    From Alvotech
    Via GlobeNewswire
    Alvotech Appoints Sarah Tanksley as Chief Quality Officer
    From Alvotech
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.